Search

Displaying results 1801 - 1810 of 7604 in total
  1. Drug

    Alteplase

    go.drugbank.com/drugs/DB00009
    ApprovedInvestigational

    [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.

  2. Drug

    Sulfanilamide

    go.drugbank.com/drugs/DB00259
    ApprovedWithdrawn

    Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.

  3. Drug

    Capsicum oleoresin

    go.drugbank.com/drugs/DB11131
    Approved

    Due to its analgesic properties, capsicum oleoresin is used to temporarily relieve of minor aches and pains of muscles and joints as an active ingredient in topical OTC preparations and has been studied

    Mixtures: Herbalax Forte No 70 Tab, HO YAN HOR MEDICATED OIL
  4. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … [L63934] The FDA approved centanafadine on July 24, 2026, for the treatment of ADHD in adults and pediatric patients 6 years of age and older weighing at least 20 kg; use is not recommended below that

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Icatibant

    go.drugbank.com/drugs/DB06196
    ApprovedInvestigational

    [A4017,A263046] Icatibant was approved by the FDA on August 25, 2011, and by the EMA in 2008 as a treatment for hereditary angioedema. … relief was observed to be 8 hours compared to 36 hours for the placebo treatment.

    Categories: Analgesics, Non-Narcotic
  6. Drug

    Fitusiran

    go.drugbank.com/drugs/DB15002
    ApprovedInvestigational

    [L52860] Fitusiran was first approved by the FDA on March 28, 2025, as routine prophylaxis therapy to prevent or reduce the frequency of bleeding episodes associated with hemophilia A or B. … [L52865] By causing the degradation of antithrombin mRNA and promoting thrombin generation, fitusiran works to restore hemostasis in patients with hemophilia.[A273770]

  7. Drug

    Amifostine

    go.drugbank.com/drugs/DB01143
    ApprovedInvestigational

    A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.

  8. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-cyclobutylmethyl-4,5α-epoxy-3,6α,14-morphinantriol
  9. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    [L8863] Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer

  10. Drug

    Dorzolamide

    go.drugbank.com/drugs/DB00869
    ApprovedInvestigational

    [L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. … Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and

    Mixtures: DORZOLOL® UD